Visteon cuts 2026 adjusted EBITDA outlook to $370 million-$410 million on warranty charges
Bitget2026/10/22 11:33- Visteon raised its full-year 2026 sales forecast by $25 million to $3.8 billion-$3.85 billion, with launches offsetting lower customer production.
- Adjusted EBITDA guidance fell to $370 million-$410 million, including $77 million in exceptional warranty charges.
- Adjusted free cash flow is projected at $90 million-$130 million, with the midpoint reduced to reflect strategic inventory building.
- Fourth-quarter demand remains strong, but tightening memory and semiconductor supplies limit further sales upside.
- Third-quarter sales reached $970 million, with growth-over-market of 10% driven by product launches.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
